Skip to main content

Table 2 The main features of 11 included studies in prognostic meta-analysis

From: The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

First authorYearCountryEthnicityCaseOutcomeHR (95%CIs)P value 
Mitch Raponi [28]2009AmericaCaucasian54OS2.30 (1.00–5.60)0.060 
Motonobu Saito (1) [29]2011JapanCaucasian89PFS2.37 (1.27–4.42)0.006 
Motonobu Saito (2) [29]2011JapanCaucasian37PFS1.60 (0.73–3.52)0.245 
Motonobu Saito (3) [29]2011JapanAsian191PFS1.33 (0.77–2.29)0.309 
Yi Gao [30]2014ChinaAsian162OS2.31 (1.48–3.61)< 0.001 
Johannes Voortman [31]2010FranceCaucasian637OS0.91 (0.72–1.13)0.390 
Tom Donnem (1) [32]2011NorwayCaucasian191 (SCC)PFS0.45 (0.21–0.96)0.039 
Tom Donnem (2) [32]2011NorwayCaucasian95 (AC)PFS1.87 (1.01–3.48)0.047 
Ce´ line Sanfiorenzo [33]2013FranceCaucasian52DFS0.94 (0.15–5.74)0.008 
Xinying Xue (1) [34]2016ChinaAsian80OS0.52 (0.24–1.14)0.045 
Xinying Xue (2) [34]2016ChinaAsian80DFS0.83 (0.30–2.31)0.054 
  1. OS: overall survival; DFS: disease free survival; PFS: progression-free survival;SCC:squamous cell carcinoma;AC:Adenocarcinoma